Lab21 Promotes its Expanding Range of Immunodiagnostic Products at Arab Health with a New Human Cytomegalovirus Immunoassay

Lab21 is pleased to announce that it will be exhibiting at this year’s Arab Health Conference in Dubai where both its Diagnostic Services and Immunodiagnostic Products division will be represented. This important regional exhibition will help raise the profile of Lab21 as it expands its diagnostics businesses internationally and provide the Company with the launch platform for its new Human Cytomegalovirus (HCMV) EIA assay.

Graham Mullis CEO of Lab21 said, “This event provides Lab21 with the opportunity to show-case how Lab21 can be the partner of choice for the region with its quality infectious disease immunodiagnostic product offering and wide range of oncology and personalised medicine services. The Company is already able to provide cost-effective services with rapid turnaround times for patients in the region that need access to state-of-the-art diagnostics.”

Lab21 will use this event to provide preliminary details on the new HCMV EIA assay, the latest new product from the Immunodiagnostic Division. HCMV is a virus in the Herpes virus group, which generally has no symptoms even after infection. However, it can prove dangerous for pre and post natal infants and in immuno-compromised patients.

Dr. Berwyn Clarke CSDO stated that, “Initial data shows that the Lab21 HCMV assay is very easy to use with exceptional sensitivity and specificity profiles and seems to be able to detect serum HCMV antibodies earlier than our competitors. This product is already generating considerable interest from our current customers and has the potential to be the gold standard test for this disease area.”

Further to its international expansion strategy, Lab21’s Immunodiagnostic Division has also recently secured a number of major new tenders to supply its diagnostic products to Non Governmental Organisations (NGO) in Africa and Thailand to add to the successful recent Indian market launch of its Syphilis assay.

Stephen Hembling International Sales Manager said that, “This hard earned success has put the company in a strong position for 2009. We intend to use these NGO tenders as a means to access new markets and further support our aggressive growth plans for existing and new products.”

Please visit Lab21 at ARAB Health at stand MJ18.